Business
Adia Nutrition Inc. Announces Effectiveness of Form 10 Registration Statement - Now a Fully Reporting SEC Company and Advancing Toward Next Phase of Growth and NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, today announced that its Form 10 registration statement became effective on February 3, 2026, as anticipated and in accordance with the U.S. Securities and Exchange Commission's (SEC) prior notification.The Form 10, originally filed on December 5, 2025, was not subject to further SEC...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, today announced that its Form 10 registration statement became effective on February 3, 2026, as anticipated and in accordance with the U.S. Securities and Exchange Commission's (SEC) prior notification.","length":420,"tagName":"p"},{"type":"text","content":"The Form 10, originally filed on December 5, 2025, was not subject to further SEC review, resulting in automatic effectiveness 60 days after filing. This milestone officially transitions Adia Nutrition to full reporting status under Section 12(g) of the Securities Exchange Act of 1934. As a fully reporting company, Adia will now provide investors with enhanced transparency through the filing of audited annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other required disclosures-standards that align closely with those expected of companies listed on major exchanges such as NASDAQ.","length":630,"tagName":"p"},{"type":"text","content":""This achievement marks a transformative step in Adia Nutrition's evolution," said Larry Powalisz Adia's CEO. "Becoming a fully reporting SEC registrant demonstrates our commitment to best-in-class governance, accountability, and investor confidence. With this foundation now in place, we are accelerating preparations for potential uplisting to the NASDAQ Capital Market, while continuing to scale our regenerative medicine platform, expand our clinic network, and advance groundbreaking treatments in stem cell therapy."","length":550,"tagName":"p"},{"type":"text","content":"The effectiveness of the Form 10 follows a series of strong recent developments, including:","length":91,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The appointment of Dr. Brian Browning as Lead Physician for all orthopedic treatments and specialties at Adia Med (announced February 2, 2026).","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The upcoming nationwide airing of a documentary featuring WWE/TNA superstar Elias/Elijah (Jeff Sciullo)'s recovery using Adia Med's AdiaVita stem cell treatment.","length":169,"tagName":"p","att...